R&G PharmaStudies Co., Ltd. (SHE:301333)
China flag China · Delayed Price · Currency is CNY
67.63
-0.99 (-1.44%)
At close: Apr 21, 2026

R&G PharmaStudies Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
6,4925,6664,7566,1904,940-
Market Cap Growth
28.77%19.12%-23.17%25.30%--
Enterprise Value
4,7703,9603,1244,5643,498-
Last Close Price
67.6359.5549.8363.8950.84-
PE Ratio
47.2941.3933.9238.0943.55-
Forward PE
39.0933.1325.30---
PS Ratio
7.636.666.398.587.75-
PB Ratio
3.292.872.593.533.10-
P/TBV Ratio
3.483.042.753.583.14-
P/FCF Ratio
68.3959.6835.2935.8545.06-
P/OCF Ratio
56.8549.6130.7332.1537.87-
EV/Sales Ratio
5.604.654.206.335.49-
EV/EBITDA Ratio
33.3930.6221.6429.6931.68-
EV/EBIT Ratio
38.9332.3225.8134.8133.97-
EV/FCF Ratio
50.2541.7223.1826.4331.90-
Debt / Equity Ratio
0.010.010.040.010.010.03
Debt / EBITDA Ratio
0.130.130.460.050.130.08
Debt / FCF Ratio
0.190.190.530.050.140.14
Net Debt / Equity Ratio
-0.88-0.88-0.93-0.97-0.94-0.80
Net Debt / EBITDA Ratio
-13.38-13.38-11.81-11.03-13.64-2.59
Net Debt / FCF Ratio
-18.22-18.22-12.65-9.82-13.74-4.60
Asset Turnover
0.360.360.340.370.501.01
Inventory Turnover
8.948.948.048.338.3610.43
Quick Ratio
5.445.444.736.206.252.35
Current Ratio
5.605.604.886.386.452.58
Return on Equity (ROE)
7.26%7.26%7.90%9.73%11.24%25.91%
Return on Assets (ROA)
3.23%3.23%3.43%4.14%5.03%11.35%
Return on Invested Capital (ROIC)
47.34%57.84%113.70%159.47%104.63%136.45%
Return on Capital Employed (ROCE)
6.10%6.10%6.40%7.50%6.40%24.60%
Earnings Yield
2.11%2.42%2.95%2.63%2.30%-
FCF Yield
1.46%1.68%2.83%2.79%2.22%-
Dividend Yield
0.23%0.27%0.32%0.31%0.31%-
Payout Ratio
8.61%8.61%20.24%3.58%--
Buyback Yield / Dilution
-0.36%-0.36%0.64%-16.78%-14.43%0.38%
Total Shareholder Return
-0.13%-0.09%0.96%-16.46%-14.12%0.38%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.